The effect of osteonection on prostate cancer and bone metastasis

• Project/Area Number: 23791747
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Urology
• Research Institution: Kanazawa University
• Principal Investigator: MIWA Sotaro 金沢大学, 医学系, 協力研究員 (80507070)
• Project Period (FY): 2011 – 2012
• Project Status: Completed (Fiscal Year 2012)
• Budget Amount: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000); Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2011: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
• Keywords: 前立腺癌 / SPARC / インテグリンβ1 / AKT / インテグリンβ１ / オステオネクチン

Research Abstract

SPARC (Secreted Protein and Rich in Cysteine, osteonectin) is extracellular matrix protein. We identified effects of SPARC on prostate cancer.Expression of SPARC decreased with stromal cells derived from prostate cancer. SPARC inhibited the proliferation of prostate cancer cells and migrating ability by inhibiting the phosphorylation of AKT. It came to light that the effects of these SPARC acted after SPARC bound to integrin beta 1 directly.

Research Products

• [Journal Article] Exogenous SPARC suppresses proliferation and migration of prostate cancer by interacting with integrin beta1 (2013)
  • Author(s): Shin M, Mizokami A, Kim J, Ofude M, Konaka H, Kadono Y, Kitagawa Y, Miwa S, Kumaki M, Keller ET, Namiki M
  • Journal Title: Prostate Volume: 73(11) Issue: 11 Pages: 1159-1170
  • DOI: 10.1002/pros.22664
  • Peer Reviewed
• [Presentation] Osteonectin suppresses proliferation and migration of human prostate cancer cells (2013)
  • Author(s): Minkyoung Shin, Atsushi Mizokami, Jungim Kim, Mitsuo Ofude, Hiroyuki Konaka, Yoshifumi Kadono, Yasuhide kitagawa, Sotaro miwa, Misako Kumaki, Evan T. Keller, and Mikio Namiki
  • Organizer: AACR 2013
  • Place of Presentation: Washington,D.C.Convention Center,USA
  • Year and Date: 2013-04-09